Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Deferred Taxes (2017 - 2025)

Corcept Therapeutics (CORT) has disclosed Deferred Taxes for 9 consecutive years, with -$15.2 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes fell 293.52% to -$15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$37.5 million through Dec 2025, up 6.6% year-over-year, with the annual reading at -$37.5 million for FY2025, 6.6% up from the prior year.
  • Deferred Taxes hit -$15.2 million in Q4 2025 for Corcept Therapeutics, down from $9.1 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $9.1 million in Q3 2025 to a low of -$17.8 million in Q2 2025.
  • Historically, Deferred Taxes has averaged -$6.8 million across 5 years, with a median of -$8.0 million in 2023.
  • Biggest five-year swings in Deferred Taxes: plummeted 678.8% in 2022 and later soared 159.93% in 2025.
  • Year by year, Deferred Taxes stood at $2.3 million in 2021, then plummeted by 294.3% to -$4.5 million in 2022, then increased by 17.8% to -$3.7 million in 2023, then fell by 5.07% to -$3.9 million in 2024, then plummeted by 293.52% to -$15.2 million in 2025.
  • Business Quant data shows Deferred Taxes for CORT at -$15.2 million in Q4 2025, $9.1 million in Q3 2025, and -$17.8 million in Q2 2025.